Elsevier

Gene

Volume 159, Issue 1, 14 June 1995, Pages 113-121
Gene

Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility-a review

https://doi.org/10.1016/0378-1119(94)00448-2Get rights and content

Abstract

Up to 90% of all cancers are possibly caused by environmental factors, such as tobacco smoke, diet and occupational exposures. The majority of chemical carcinogens require metabolic activation before they interact with cellular macromolecules and can cause cancer initiation. The xenobiotic-metabolising machinery contains two main types of enzymes: the phase-1 cytochromes P-450 (CYP) mediating oxidative metabolism, and phase-II conjugating enzymes. Several phase-I and phase-II genes have recently been cloned and identified in humans. Many of them show polymorphism and have been suggested to contribute to individual cancer susceptibility as genetic modifiers of cancer risk. Altered phenotypes and genotypes in the CYP subfamilies CYP1A1, CYP2D6 and CYP2E1 have been associated with tobacco smoke-induced lung cancer and other cancers. Defective glutathione S-transferase (GST) and N-acetyltransferase (NAT) enzymes have been associated with an increased risk of developing lung and bladder cancer. There are also several studies in each category in which no associations have been found. The risk of developing lung cancer is dramatically (up to 40-fold) elevated in subpopulations having simultaneously high-risk genotypes in CYPI A1 and GSTM1. There are several difficulties in this area of research. First, many of the observed restriction-fragment length polymorphisms (RFLPs) are due to mutations in introns or other silent areas of DNA, raising the possibility that any associations found between RFLPs and cancer occur only by chance. Second, biologically plausible mechanisms linking genotypes and cancer are lacking in most of the observed cases. Third, substantial ethnic differences have been shown to exist in the distribution of defective and functionally normal alleles, making extrapolations from one ethnic group to another impossible. Thus, it is still difficult to say to what extent tests based on the polymerase chain reaction (PCR) and other methodology will be used to in the future to predict an individual's susceptibility to cancers caused by xenobiotics.

References (66)

  • H. Raunio et al.

    Immunochemical detection of human liver cytochrome P450 forms related to phenobarbital-inducible forms in the mouse

    Biochem. Pharmacol.

    (1990)
  • J.A.G. Agundez et al.

    Debrisoquin oxidation genotype and susceptibility to lung cancer

    Clin. Pharmacol. Ther.

    (1994)
  • S. Anttila et al.

    Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450IA in lung cancer patients

    Int. J. Cancer

    (1991)
  • S. Anttila et al.

    Immunohistochemical localization of glutathione S-transferase in human lung

    Cancer Res.

    (1993)
  • S. Anttila et al.

    Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on histological type of lung cancer

    Carcinogenesis

    (1994)
  • D.A. Bell et al.

    Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase μ

    Environ. Health Perspect.

    (1992)
  • D.A. Bell et al.

    Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen metabolism gene glutathione transferase μ (GSTM1) increases susceptibility to bladder cancer

    J. Natl. Cancer Inst.

    (1993)
  • M. Blum et al.

    Molecular mechanism of slow acetylation of drugs and carcinogens in humans

  • J. Brockmöller et al.

    Genotype and phenotype of glutathione S-transferase class μ isoenzymes μ and ψ in lung cancer patients and controls

    Cancer Res.

    (1993)
  • N. Caporaso et al.

    Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence

    Pharmacogenetics

    (1991)
  • A.K. Daly et al.

    Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer

    Br. Med. J.

    (1993)
  • A.C. Gough et al.

    Identification of the primary gene defect at the cytochrome P450 CYP2D locus

    Nature

    (1990)
  • F.P. Guengerich

    Bioactivation and detoxication of toxic and carcinogenic chemicals

    Drug Metab. Dispos.

    (1993)
  • S.I. Hayashi et al.

    Genetic linkage of lung cancer-associated Mspl polymorhisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene

    J. Biochem.

    (1991)
  • S. Hayashi et al.

    Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene

    J. Biochem.

    (1991)
  • S. Hayashi et al.

    High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes

    Jpn. J. Cancer Res.

    (1992)
  • R.B. Hayes et al.

    N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers

    Carcinogenesis

    (1993)
  • A. Hirvonen et al.

    Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1 A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population

    Cancer Epidem. Biomarkers Prevention

    (1992)
  • A. Hirvonen et al.

    PCR-based CYP2D6 genotyping for Finnish lung cancer patients

    Pharmacogenetics

    (1993)
  • A. Hirvonen et al.

    The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population

    Carcinogenesis

    (1993)
  • A. Hirvonen et al.

    The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung

    Carcinogenesis

    (1993)
  • A. Hirvonen et al.

    Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers

    Carcinogenesis

    (1994)
  • IARC
  • Cited by (0)

    Presented at the Joint Meeting and Laboratory Course “Research in Gene Diagnostics of Cancer Disease”, Münster/Witten, Germany, 24–28 October, 1994.

    View full text